Martine Rothblatt, Chairperson and Chief Executive Officer of United Therapeutics Corp (NASDAQ: UTHR), disclosed the sale of common stock totaling approximately $5.3 million on April 2, 2026. According to the Form 4 filing with the Securities and Exchange Commission, the shares were sold at prices between $552.2469 and $571.6633 per share.
The filing shows that Rothblatt sold 6,921 shares of United Therapeutics common stock on that date. The same Form 4 records that Rothblatt exercised stock options to purchase 9,500 shares of common stock at an exercise price of $146.03 per share, representing a total cash outlay of $1,387,285.
After completing these transactions, Rothblatt directly holds 40,513 shares of United Therapeutics common stock. The filing also itemizes Rothblatt's indirect holdings: 166 shares held by a spouse, and four trust accounts holding 324,518; 258,117; 45,596; and 10,962 shares, respectively.
The sales and the option exercise were carried out under a pre-arranged 10b5-1 trading plan that Rothblatt adopted on November 7, 2025, the filing notes. The Form 4 serves as the formal SEC disclosure of these insider transactions.
Analyst reaction and related market moves
United Therapeutics has attracted heightened analyst focus following positive results from its Phase 3 TETON-1 trial evaluating Tyvaso in idiopathic pulmonary fibrosis. Multiple investment firms adjusted their price targets in response to the trial data.
- H.C. Wainwright raised its price target for United Therapeutics to $660 and maintained a Buy rating, citing the TETON-1 data as supportive of expanding Tyvaso.
- BofA Securities increased its price target to $626 while keeping a Neutral rating, noting the trial as a second confirmatory study for Tyvaso in the indication.
- Jefferies moved its target to $733 and retained a Buy rating, describing the trial as improving the probability of success for the drug in idiopathic and progressive pulmonary fibrosis relative to prior studies outside the U.S. and Canada.
Those trial readouts have also had spillover effects in the broader pulmonary and specialty respiratory sector. Insmed experienced a stock uptick after Morgan Stanley upgraded the company to Overweight, citing positive data from United Therapeutics and reporting strong prescribing trends for Insmed's Brinsupri in bronchiectasis according to a proprietary survey.
Implications for investors
The Form 4 provides the formal record of Rothblatt's April 2 trading activity and the option exercise. Separately, the TETON-1 results and subsequent analyst adjustments have generated wider attention across the pulmonary fibrosis and specialty respiratory therapy market segments.
Investors and market participants evaluating United Therapeutics will see the insider filing alongside the recent analyst commentary and peer market activity as contemporaneous disclosures relevant to company ownership, clinical progress, and market expectations.